Stock Movers: Wizz Air, Wise, Bayer (podcast)
On this episode of Stock Movers: - Wizz Air plunged 26% in early trading after the discount airline reported earnings that missed estimates and refrained from providing a guidance, citing poor visibility. - Wise is planning to list its shares in the US, the latest blow to London's stock market. - Bayer shares rise as much as 5.1% after Goldman Sachs upgrades the German chemicals and pharmaceutical company to buy from neutral, saying it sees earnings as having bottomed out and thinks risks around litigation and pharma data are overdone.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
Red Lobster's 36-year-old CEO started as a Goldman Sachs intern. He reveals 3 bold moves he's cooking up for the seafood chain's comeback
Red Lobster CEO Damola Adamolekun came from a private equity and finance background, breaking into the restaurant industry through a successful deal he navigated. The former P.F. Chang's CEO outlined the changes he's enacting to save the beleaguered seafood chain from bankruptcy and to make it the beloved brand it once was. Damola Adamolekun reached the pinnacle of restaurant leadership in a somewhat unconditional way. Although the Red Lobster CEO waited tables back in high school, his first big career move was landing an internship with global investment bank Goldman Sachs at age 19. At the time, Adamolekun was a student athlete at Brown University, where he studied economics and political science. He continued to work as an analyst with Goldman Sachs following graduation for a couple of years, then moved on to become a private equity associate with TPG Capital, where he worked until 2015. But Adamolekun's big break came while he was a partner at hedge fund Paulson & Co., which now operates as a family office. In 2019, Paulson purchased Asian-inspired restaurant chain P.F. Chang's in a $700 million deal. Adamolekun said during a podcast episode of The Breakfast Club that he was the one who pitched the idea to buy P.F. Chang's to the firm. 'I thought we could do a lot of new things with it. We could add delivery, we could remodel the restaurants. We could make it more interesting,' Adamolekun said. The deal was successful—until the pandemic hit, wiping out restaurant and retail businesses. The P.F. Chang's CEO even stepped down during COVID, and Adamolekun had to 'rescue the situation,' he said. And with that, Adamolekun stepped in as CEO, officially charting his path to become a revered restaurant executive. The P.F. Chang's deal 'ended up being a really good deal, but not without a lot of blood, sweat, and tears for a few years,' Adamolekun said. He masterminded a plan to remodel the chain's restaurants and revamp the menu—and is largely using the same playbook as CEO of Red Lobster. Adamolekun, 36, took over as CEO of Red Lobster in September, as the seafood chain was crawling from the ashes of bankruptcy. He has a three-pillar roadmap for reviving Red Lobster, particularly in the aftermath of its endless-shrimp debacle. One of the biggest mistakes Red Lobster made was its endless-shrimp promotion. Because guests took advantage of the bonkers deal by consuming pound after pound of shrimp, the seafood chain ended up losing millions of dollars. So, needless to say, Adamolekun is steering clear of any future bottomless-shrimp promotions in the future. Instead, he's focused on revamping the seafood chain's menu. 'There's a lot of chain restaurants, [but] there's only one that serves lobster and crab the way we do,' Adamolekun told The Breakfast Club. The seafood chain is leaning into that differentiator, and one new crab dish has become Adamolekun's favorite. Adamolekun's master plan for reinvigorating Red Lobster includes remodeling the chain's 545 restaurants. But remodeling at that scale takes time—and money. For now, Adamolekun has implemented small changes, like changing up the music diners listen to while at the restaurant. 'We fix the things we can fix quickly,' he said during the podcast. 'The music is better.' The restaurant chain has also printed market prices for lobsters on table liners, and will continue to implement 'small things you can do now.' 'But comprehensively there needs to be a remodel…and that's something that we'll do in the future, I think,' Adamolekun said. Another cost-effective way the restaurant chain is making incremental improvements is through service and hospitality changes. Service workers are expected to greet guests more quickly and be more attentive. And Red Lobster has already seen tangible improvements from service changes. The restaurant chain tracks a sentiment score, which is a net positive versus negative sentiment, Adamolekun explained, or what people are saying is good versus bad at Red Lobster. The sentiment score was only 30 when he first took over, but last month it had doubled to 60, Adamolekun said during the podcast. 'When you go to Red Lobster next, you'll see it's going to feel different,' Adamolekun told The Breakfast Club. A version of this story originally published on on February 26, 2025. This story was originally featured on
Associated Press
an hour ago
- Associated Press
Sire Search Identifies Top 5 Platforms to Boost Biotech Career Growth
Hey, biotech folks! Whether you're a lab whiz itching to land your next role in drug discovery or a hiring manager hunting for the perfect candidate to boost your startup, the life sciences world is buzzing with potential. But, real talk—finding the right job or talent in this fast-moving industry can feel like trying to spot a single cell under a microscope. Overwhelming, right? That's were specialized recruitment websites swoop in like career superheroes. I've rounded up the five best platforms to help you navigate the biotech job maze, and guess what? SIRE Searchis leading the charge with its sharp, tailored approach. Let's dive in and see why these sites are your new allies for crushing it in biotech! 1. – Your Career's Guide A recruitment platform that feels like it knows you better than your lab partner. That's SIRE Searchin a nutshell. Based in Haarlem, Netherlands—a charming spot, by the way—SIRE has been shaking up the life sciences scene since 2012. Whether you're into pharmaceuticals, medical devices, or even fast-moving consumer goods (yep, they've got that covered), SIRE's the place to find your next career win. Their reverse recruitment approach is like a secret weapon. Instead of tossing a pile of job listings your way, they do the heavy lifting first. Using data and market insights, their team—packed with recruiters who actually get biotech—handpicks roles that match your skills and goals. One Trustpilot reviewer raved, 'SIRE landed me a job that's spot-on for my expertise. They were quick and genuinely cared!' With a 4-star rating, they're clearly hitting the mark. 2. – The U.S. Biotech Hub Let's zip over to the States for BioSpace, a heavyweight for biotech and pharma jobs. With over 4,000 active listings, this sites like a treasure chest for anyone looking to dive into or climb higher in the U.S. biotech scene. From lab techs to execs, BioSpace has roles for every step of your journey. What's the deal with BioSpace? It's more than a job board—it's a whole community. You can narrow down searches by niche (like gene therapy or clinical trials) or location, so you're not stuck scrolling through irrelevant posts. They also dish out extras like industry updates, career tips, and their 'Best Places to Work' report, which is like a VIP list for biotech companies. The downside? It's mostly U.S.-focused, so it doesn't have SIRE's global reach. But for North American job seekers, BioSpace is a goldmine. 3. – Your Global Career Connector Dreaming of a biotech career that takes you worldwide? Meet Preclinical. With offices in places like the UK, Singapore, and the U.S., this platform hooks up candidates with roles in everything from drug development to regulatory affairs. It's like having a friend who knows the hottest jobs on every continent. Proclinical's strength is precision. Their recruiters dig into what employers need—skills, culture, the whole package—and match that with a huge candidate network. It's like they're playing career matchmaker, and they're good at it. They don't have SIRE's data-driven reverse recruitment trick, but their global scope is a big win for anyone wanting to think beyond borders. Plus, their blog's full of practical tips, like how to tweak your CV or nail an interview, which is super handy. 4. – The Science Lover's Hangout Next up is New Scientist Jobs, the friendly, all-purpose spot for science buffs. It covers a range of fields, but its biotech section is packed with roles in areas like vaccine research or molecular biology. Whether you're in Europe, the U.S., or elsewhere, this platform's global vibe makes it a welcoming place to explore. Why's it worth your time? It's easy to navigate, with filters to zero in on jobs by expertise or location. Their blog's a gem, too, with career advice and industry scoops that keep you in the loop. It's not as biotech-focused as SIRE, so you might need to sift a bit to find the right role. But if you're curious and love poking around, New Scientist Jobs is a solid bet. 5. – The Job-Finding Shortcut Last up is BioPharmGuy, the quirky underdog we're rooting for. Instead of hosting job listings, it points you straight to biotech company career pages, helping you dodge crowded job boards and find hidden opportunities. It's like a map of buried treasure. You can search by region or niche—like cell therapy or diagnostics—which makes it easy to target your sweet spot. The catch? It's more of a DIY experience, so you won't get the hands-on support you'd find with SIRE's recruiters. But for those who enjoy a bit of career sleuthing, BioPharmGuy is a clever tool to stand out. Why SIRE Search Takes the Crown? Let's give a shoutout to SIRE Searchfor stealing the show. Their reverse recruitment strategy is like having a career coach who's always one step ahead. By tapping into data and market trends, they find roles that fit you like a perfectly calibrated pipette. Their recruiters are biotech enthusiasts who speak your language and genuinely care about your next step. SIRE's focus on Europe—where biotech is thriving—gives them the edge, with connections to everyone from tiny startups to massive corporations. One candidate on Trustpilot said, 'SIRE made my job search feel effortless. They found me a role that's exactly where I want to be.' Employers love them, too, thanks to their knack for delivering candidates who nail both the skills and the vibe. Whether you're after a temp role or a corner office, SIRE's your partner in crime. 5 Tips to Nail Your Biotech Job Hunt Ready to hit these websites and land your dream role? Here's how to make it happen: Let's Wrap It Up The biotech world is full of possibilities, and these websites are your key to unlocking them. SIRE Searchleads the pack with its smart, personalized approach and deep love for life sciences. BioSpace, Preclinical, New Scientist Jobs, and BioPharmGuy are also stellar, each bringing their spark to the table. So, spruce up that resume, dive into these platforms, and get ready to make waves in biotech. Your next big opportunity is out there—grab it! Media Contact Company Name: Sire Search Email: Send Email Address:Staten Bolwerk City: 12011 MK Haarlem Country: Netherlands Website: Press Release Distributed by To view the original version on ABNewswire visit: Sire Search Identifies Top 5 Platforms to Boost Biotech Career Growth
Associated Press
an hour ago
- Associated Press
CCV Group Invests in Rezonate to Redefine the Future of Music Royalties for Producers and Creators
United Kingdom, June 6, 2025 -- CCV Group ( ), a venture capital firm focused on the intersection of culture, media, and technology, is proud to announce a strategic investment in Rezonate, a pioneering rights platform reshaping how music producers and back-end creators monetize their work. Founded by acclaimed producer Cam Blackwood and former investment banker Tom Tyler, Rezonate is building a new asset class by acquiring and managing royalty streams from music producers, engineers, and other behind-the-scenes talent. The company leverages cutting-edge data and rights tracking to ensure transparency, equity, and long-term value in an industry that has historically undervalued these contributors. Rezonate is also backed by Bridgepoint, one of Europe's most experienced credit managers, which in June announced the provision of up to $150 million worth of capital to accelerate the platform's growth and fuel a pipeline of high-profile producer catalogue acquisitions. Today's investment will accelerate Rezonate's growth across Europe and the U.S., scale its acquisition pipeline, and further build out its proprietary platform for rights management. John Darling, CEO of CCV Group, said: 'We believe the next wave of cultural value will be built on infrastructure that respects and empowers creators. Rezonate is unlocking a hidden layer of music IP—bringing transparency, liquidity, and dignity to the producers and engineers who shape the sound of generations. This is exactly the kind of cultural infrastructure we're here to back.' Cam Blackwood, Producer and Co-founder of Rezonate, said: 'For years, producers and engineers have shaped iconic records without sharing in their long-term value. Rezonate is about fixing that—giving creative professionals the financial tools and recognition they've always deserved. We're thrilled to have CCV's support as we scale this mission globally.' Tom Tyler, Co-founder of Rezonate, said: 'We're building an institutionally credible, data-led platform that can manage and grow the royalty income of the music industry's unsung heroes. With CCV's investment, we're not just gaining capital we're gaining a partner that understands the long-term thesis around creator-led IP.' This partnership signals a broader shift in the music rights landscape. While most funds focus on front-facing artist catalogs, Rezonate is leading a new movement focused on backend creators those who've traditionally had fewer paths to liquidity or legacy building. About CCV Group CCV Group is a venture capital firm investing in early and growth-stage companies at the intersection of culture, technology, and media. With a team of experienced founders and operators, CCV partners with bold entrepreneurs to build enduring companies that shape the cultural economy. About Rezonate Rezonate is a rights management and royalty acquisition company focused on music producers, engineers, and creators behind the scenes. By combining rights aggregation, financial structuring, and advanced metadata tracking, Rezonate empowers creators to unlock and protect the long-term value of their work. About Bridgepoint Bridgepoint Group is one of the world's leading quoted private asset growth investors, specialising in private equity, infrastructure and private credit. With over $75 billion of assets under management and a strong local presence in Europe, North America and Asia, they combine global scale with local market insight and sector expertise, consistently delivering strong returns through cycles. Contact Info: Name: John Darling Email: Send Email Organization: Creative Capital Ventures Website: Release ID: 89161804 If there are any errors, inconsistencies, or queries arising from the content contained within this press release that require attention or if you need assistance with a press release takedown, we kindly request that you inform us immediately by contacting [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our reliable team will be available to promptly respond within 8 hours, taking proactive measures to rectify any identified issues or providing guidance on the removal process. Ensuring accurate and dependable information is our top priority.
